← Back to Search

EUS + Liver Biopsy for Liver Disease

N/A
Waitlist Available
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare two methods for liver biopsy and measuring portal pressure.

Who is the study for?
This trial is for adults over 18 who need a liver biopsy and portal pressure measurement due to chronic liver disease or portal hypertension. It's not for those on certain blood thinners, with altered digestive anatomy, severe fluid in the abdomen, liver vein clots, past liver transplant, allergy to specific sedatives, psychotic disorders, pregnancy, or significant clotting or platelet issues.
What is being tested?
The study compares two methods of measuring portal pressure and obtaining liver biopsies: an endoscopic ultrasound (EUS) approach versus the standard transjugular (TJ) hepatic venous method. The goal is to see which one provides better results as part of patient care.
What are the potential side effects?
Potential side effects may include discomfort at the biopsy site, bleeding risks especially if there are existing clotting problems; reactions to sedatives used during procedures like midazolam or ketamine; and complications related to underlying health conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Compare the proportion of adequate Liver Biopsy specimens with reliable portal pressure gradient obtained by TJ or EUS
Secondary study objectives
Adverse events
Biopsy
PPG-related outcomes
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Transjugular approachExperimental Treatment1 Intervention
Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).
Group II: Endoscopic ultrasound approachExperimental Treatment1 Intervention
Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,949 Total Patients Enrolled
2 Trials studying Liver Cirrhosis
34 Patients Enrolled for Liver Cirrhosis

Media Library

Endoscopic ultrasound portal pressure gradient measurement with liver biopsy Clinical Trial Eligibility Overview. Trial Name: NCT05118308 — N/A
Liver Cirrhosis Research Study Groups: Endoscopic ultrasound approach, Transjugular approach
Liver Cirrhosis Clinical Trial 2023: Endoscopic ultrasound portal pressure gradient measurement with liver biopsy Highlights & Side Effects. Trial Name: NCT05118308 — N/A
Endoscopic ultrasound portal pressure gradient measurement with liver biopsy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05118308 — N/A
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top